US EditionMounjaro Price Increase Sees Patients Switch to Cheaper Wegovy
Ozempic sales rose 500 to 600% after Mounjaro's price nearly tripled from £122 to £330, making Ozempic half the competitor's cost, industry experts said.
- Eli Lilly will nearly triple the price of Mounjaro on September 1, leading many UK patients to seek cheaper alternatives like Wegovy.
- This price hike follows Eli Lilly's initial UK launch at a significantly lower price than other European markets to ensure NHS availability.
- Wegovy and Mounjaro are weekly GLP-1 injection drugs originally for type 2 diabetes, with Wegovy mimicking gut hormone GLP-1 to curb appetite.
- A pharmacy expert from Chemist4U emphasizes that patients should only change their medication under professional guidance, as dosage needs to be carefully adjusted based on their health condition and previous treatments.
- The price rise is driving demand for Wegovy, shown by a 5,500% spike in searches about switching, which may affect patient weight loss journeys and pharmacy stock levels.
Insights by Ground AI
Does this summary seem wrong?
14 Articles
14 Articles
DEXYPTAGE - The US laboratory Eli Lilly has already increased the price of Mounjaro, its treatment for obesity, by 170% in England.
·Paris, France
Read Full Article
I am on the farm market! The price of a medicine explodes in Europe by 170%! One of the most popular treatment against type 2 diabetes and obesity, Mounjaro, is saving considerable in Europe. American giant Eli Lilly announced an increase of 170% of the list price in the UK, as it enters into force from [...]
·Romania
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
